According to the International Diabetes Federation, over 500 million adults are currently living with diabetes, a number projected to rise to 700 million by 2045. This epidemic is the primary driver of the surging demand for peptide APIs, particularly GLP-1 receptor agonists like semaglutide and liraglutide, as well as next-generation insulin analogs. The glucagon-like peptide 1 (GLP-1) market has grown strongly, expanding from $22.06 billion in 2025 to $23.88 billion in 2026 at a CAGR of 8.2%[reference:47].
This unprecedented demand is putting immense pressure on global supply chains, leading to shortages and forcing manufacturers to expand their capacities rapidly. CDMOs are investing billions in new facilities and continuous manufacturing technologies to keep pace. The GLP-1 agonists weight loss drugs market alone is expected to grow from $15.5 billion in 2025 to $18.02 billion in 2026 at a CAGR of 16.3%[reference:48].
Beyond GLP-1s, research into dual and triple agonists (e.g., GLP-1/GIP/Glucagon) is opening new avenues for API development, promising even better glycemic control and weight loss outcomes, further fueling long-term demand. Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, is projected to be the top-selling drug in 2026, generating more than $45 billion in global sales[reference:49]. Novo Nordisk's semaglutide, sold as Ozempic, Wegovy, and Rybelsus, is expected to bring in $39.5 billion in sales[reference:50].
The diabetes epidemic has also spurred innovation in peptide delivery methods. Oral peptide delivery is achieving breakthrough milestones, with novel permeation enhancers and enteric coating technologies allowing for subcutaneous-to-oral switching of blockbuster drugs. Novo's Wegovy pill for weight loss debuted in early January 2026, notching more than 18,400 prescriptions in its first week[reference:51]. Lilly's orforglipron pill for weight loss is currently under expedited FDA review[reference:52].
For peptide API manufacturers, the diabetes-driven demand represents both a challenge and an opportunity. Companies that can scale up production while maintaining quality and regulatory compliance will be well-positioned to capture significant market share. The expansion of GLP-1 indications into cardiovascular, kidney, liver disease, and sleep apnea is further expanding the addressable market[reference:53], ensuring continued demand for peptide API manufacturing services well into the future.